Early therapy assessment of combined anti-DR5 antibody and carboplatin in triple-negative breast cancer xenografts in mice using diffusion-weighted imaging and 1H MR spectroscopy
Guihua Zhai PhD
The Department of Radiology, University of Alabama at Birmingham, Birmingham, Alabama, USA
Search for more papers by this authorCorresponding Author
Hyunki Kim PhD, MBA
The Department of Radiology, University of Alabama at Birmingham, Birmingham, Alabama, USA
The Department of Biomedical Engineering, University of Alabama at Birmingham, Birmingham, Alabama, USA
Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, Alabama, USA
Address reprint requests to: H.K., G082C5 Volker Hall, 1670 University Blvd., Birmingham, AL 35294-0019. E-mail: [email protected]Search for more papers by this authorDavid Sarver BS
The Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA
Search for more papers by this authorSharon Samuel BS
The Department of Radiology, University of Alabama at Birmingham, Birmingham, Alabama, USA
Search for more papers by this authorLee Whitworth BS
The Department of Radiology, University of Alabama at Birmingham, Birmingham, Alabama, USA
Search for more papers by this authorHeidi Umphrey MD
The Department of Radiology, University of Alabama at Birmingham, Birmingham, Alabama, USA
Search for more papers by this authorDenise K. Oelschlager BS
Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, Alabama, USA
Search for more papers by this authorT. Mark Beasley PhD
The Department of Biostatistics, University of Alabama at Birmingham, Birmingham, Alabama, USA
Search for more papers by this authorKurt R. Zinn PhD, DVM
The Department of Radiology, University of Alabama at Birmingham, Birmingham, Alabama, USA
Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, Alabama, USA
The Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA
Search for more papers by this authorGuihua Zhai PhD
The Department of Radiology, University of Alabama at Birmingham, Birmingham, Alabama, USA
Search for more papers by this authorCorresponding Author
Hyunki Kim PhD, MBA
The Department of Radiology, University of Alabama at Birmingham, Birmingham, Alabama, USA
The Department of Biomedical Engineering, University of Alabama at Birmingham, Birmingham, Alabama, USA
Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, Alabama, USA
Address reprint requests to: H.K., G082C5 Volker Hall, 1670 University Blvd., Birmingham, AL 35294-0019. E-mail: [email protected]Search for more papers by this authorDavid Sarver BS
The Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA
Search for more papers by this authorSharon Samuel BS
The Department of Radiology, University of Alabama at Birmingham, Birmingham, Alabama, USA
Search for more papers by this authorLee Whitworth BS
The Department of Radiology, University of Alabama at Birmingham, Birmingham, Alabama, USA
Search for more papers by this authorHeidi Umphrey MD
The Department of Radiology, University of Alabama at Birmingham, Birmingham, Alabama, USA
Search for more papers by this authorDenise K. Oelschlager BS
Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, Alabama, USA
Search for more papers by this authorT. Mark Beasley PhD
The Department of Biostatistics, University of Alabama at Birmingham, Birmingham, Alabama, USA
Search for more papers by this authorKurt R. Zinn PhD, DVM
The Department of Radiology, University of Alabama at Birmingham, Birmingham, Alabama, USA
Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, Alabama, USA
The Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA
Search for more papers by this authorAbstract
Purpose
To assess the early response of triple-negative breast-cancer (TNBC) following TRA-8 and carboplatin therapy using DWI and MRS in 2LMP and SUM159 mouse models.
Materials and Methods
Four groups (n = 5/group) of each model were untreated or treated with carboplatin, TRA-8, and combination, respectively. DWI and MRS were applied on 0, 3, and 7 days after therapy initiation, and all tumors were collected thereafter for terminal deoxynucleotidyl transferase mediated dUTP nick end labeling (TUNEL) staining. The changes in intratumoral apparent diffusion coefficient (ADC) and fat–water ratios (FWRs) were compared with tumor volume changes and apoptotic cell densities.
Results
Mean ADC values of 2LMP and SUM159 tumors significantly increased 4 ± 4% and 37 ± 11% during 7 days of combination therapy, respectively, as compared to control groups (P < 0.05). Similarly, mean FWRs of 2LMP and SUM159 tumors significantly increased 102 ± 30% and 126 ± 52%, respectively, for 7 days of combined treatment (P < 0.05). The changes of the mean ADC values for 3 days (or FWRs for 7 days) were linearly proportional to either the mean volume changes or apoptotic cell densities in both models.
Conclusion
DWI and MRS assessed the early tumor response to TRA-8 and carboplatin in TNBC mouse models. J. Magn. Reson. Imaging 2014;39:1588–1594. © 2013 Wiley Periodicals, Inc.
REFERENCES
- 1Pan G, Ni J, Wei YF, Yu G, Gentz R, Dixit VM. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science 1997; 277: 815–818.
- 2Pan G, O'Rourke K, Chinnaiyan AM, et al. The receptor for the cytotoxic ligand TRAIL. Science 1997; 276: 111–113.
- 3Walczak H, Degli-Esposti MA, Johnson RS, et al. TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL. EMBO J 1997; 16: 5386–5397.
- 4Chaudhary PM, Eby M, Jasmin A, Bookwalter A, Murray J, Hood L. Death receptor 5, a new member of the TNFR family, and DR4 induce FADD-dependent apoptosis and activate the NF-kappaB pathway. Immunity 1997; 7: 821–830.
- 5Schneider P, Thome M, Burns K, et al. TRAIL receptors 1 (DR4) and 2 (DR5) signal FADD-dependent apoptosis and activate NF-kappaB. Immunity 1997; 7: 831–836.
- 6Degli-Esposti MA, Dougall WC, Smolak PJ, Waugh JY, Smith CA, Goodwin RG. The novel receptor TRAIL-R4 induces NF-kappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain. Immunity 1997; 7: 813–820.
- 7Degli-Esposti MA, Smolak PJ, Walczak H, et al. Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family. J Exp Med 1997; 186: 1165–1170.
- 8Emery JG, McDonnell P, Burke MB, et al. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem 1998; 273: 14363–14367.
- 9Ashkenazi A, Pai RC, Fong S, et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999; 104: 155–162.
- 10.Chinnaiyan AM, Prasad U, Shankar S, et al. Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy. Proc Natl Acad Sci U S A 2000; 97: 1754–1759.
- 11Jo M, Kim TH, Seol DW, et al. Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand. Nat Med 2000; 6: 564–567.
- 12Ichikawa K, Liu W, Zhao L, et al. Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity. Nat Med 2001; 7: 954–960.
- 13Oliver PG, LoBuglio AF, Zhou T, et al. Effect of anti-DR5 and chemotherapy on basal-like breast cancer. Breast Cancer Res Treat 2011; 133: 417–426.
- 14Rahman M, Davis SR, Pumphrey JG, et al. TRAIL induces apoptosis in triple-negative breast cancer cells with a mesenchymal phenotype. Breast Cancer Res Treat 2009; 113: 217–230.
- 15Rouzier R, Perou CM, Symmans WF, et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 2005; 11: 5678–5685.
- 16Carey LA, Dees EC, Sawyer L, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 2007; 13: 2329–2334.
- 17Wheate NJ, Walker S, Craig GE, Oun R. The status of platinum anticancer drugs in the clinic and in clinical trials. Dalton Trans 2010; 39: 8113–8127.
- 18Narod SA, Foulkes WD. BRCA1 and BRCA2: 1994 and beyond. Nat Rev Cancer 2004; 4: 665–676.
- 19Lakhani SR, Reis-Filho JS, Fulford L, et al. Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin Cancer Res 2005; 11: 5175–5180.
- 20Ratanaphan A, Canyuk B, Wasiksiri S, Mahasawat P. In vitro platination of human breast cancer suppressor gene 1 (BRCA1) by the anticancer drug carboplatin. Biochim Biophys Acta 2005; 1725: 145–151.
- 21Chang HR, Glaspy J, Allison MA, et al. Differential response of triple-negative breast cancer to a docetaxel and carboplatin-based neoadjuvant treatment. Cancer 2010; 116: 4227–4237.
- 22EI-Gazzar A, Perco P, Eckelhart E, et al. Natural immunity enhances the activity of a DR5 agonistic antibody and carboplatin in the treatment of ovarian cancer. Mol Cancer Ther 2010; 9: 1007–1018.
- 23Galons JP, Altbach MI, Paine-Murrieta GD, Taylor CW, Gillies RJ. Early increases in breast tumor xenograft water mobility in response to paclitaxel therapy detected by non-invasive diffusion magnetic resonance imaging. Neoplasia 1999; 1: 113–117.
- 24Woodhams R, Matsunaga K, Kan S, et al. ADC mapping of benign and malignant breast tumors. Magn Reson Med Sci 2005; 4: 35–42.
- 25Woodhams R, Matsunaga K, Iwabuchi K, et al. Diffusion-weighted imaging of malignant breast tumors: the usefulness of apparent diffusion coefficient (ADC) value and ADC map for the detection of malignant breast tumors and evaluation of cancer extension. J Comput Assist Tomogr 2005; 29: 644–649.
- 26Rubesova E, Grell AS, De Maertelaer V, Metens T, Chao SL, Lemort M. Quantitative diffusion imaging in breast cancer: a clinical prospective study. J Magn Reson Imaging 2006; 24: 319–324.
- 27Schmitz JE, Kettunen MI, Hu DE, Brindle KM. 1H MRS-visible lipids accumulate during apoptosis of lymphoma cells in vitro and in vivo. Magn Reson Med 2005; 54: 43–50.
- 28Jagannathan NR, Singh M, Govindaraju V, et al. Volume localized in vivo proton MR spectroscopy of breast carcinoma: variation of water-fat ratio in patients receiving chemotherapy. NMR Biomed 1998; 11: 414–422.
10.1002/(SICI)1099-1492(199812)11:8<414::AID-NBM537>3.0.CO;2-W CAS PubMed Web of Science® Google Scholar
- 29Kumar M, Jagannathan NR, Seenu V, Dwivedi SN, Julka PK, Rath GK. Monitoring the therapeutic response of locally advanced breast cancer patients: sequential in vivo proton MR spectroscopy study. J Magn Reson Imaging 2006; 24: 325–332.
- 30Medina-Carnicer R, Madrid-Cuevas FJ, Fernadez-Carcia NL, Carmona-Poyato A. Evaluation of global thresholding techniques in non-contextual edge detection. Pattern Recognit Lett 2005; 26: 1423–1434.
- 31Naressi A, Couturier C, Devos J, et al. Java-based graphical user interface for the MRUI quantification package. Magn Reson Mater Phys Biol Med 2001; 12: 141–152.
- 32Kim H, Morgan DE, Zeng H, et al. Breast tumor xenografts: diffusion-weighted MR imaging to assess early therapy with novel apoptosis-inducing anti-DR5 antibody. Radiology 2008; 248: 844–851.
- 33Sternberg SR. Biomedical image processing. IEEE Computer 1983; 16: 22–34.
- 34Neter J, Kutner MH, Nachtsheim JC, et al. Applied linear statistical models. Columbus: The McGraw-Hill Companies, Inc; 1996.
- 35Rodgers JL, Nicewander WA. Thirteen ways to look at the correlation coefficient. Am Stat 1988; 42: 59–66.
- 36Delikatny EJ, Cooper WA, Brammah S, Sathasivam N, Rideout DC. Nuclear magnetic resonance-visible lipids induced by cationic lipophilic chemotherapeutic agents are accompanied by increased lipid droplet formation and damaged mitochondria. Cancer Res 2002; 62: 1394–1400.
- 37Hamilton G, Yokoo T, Bydder M, et al. In vivo characterization of the liver fat 1H MR spectrum. NMR Biomed 2011; 24: 784–790.
- 38Tozaki M, Sakamoto M, Oyama Y, Maruyama K, Fukuma E. Predicting pathological response to neoadjuvant chemotherapy in breast cancer with quantitative 1H MR spectroscopy using the external standard method. J. Magn Reson Imaging 2010; 31: 895–902.
- 39Monsma DJ, Monks NR, Cherba DM, et al. Genomic characterization of explant tumorgraft models derived from fresh patient tumor tissue. J Transl Med 2012; 10: 125.
